News

- Integrated lead optimisation to advance APEIRON’s Cbl-b inhibitor development programme APN431

- Inhibitors discovered at Domainex via virtual and fragment screening


Vienna, Austria and Saffron Waldon, UK, 9th November 2020 / Sciad Newswire / APEIRON Biologics AG, a privately-held biotech company developing breakthrough therapies to treat cancer and respiratory conditions, has selected Domainex Ltd to provide integrated lead optimisation services in order to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b through small molecule drug discovery.

Find out what we're up to in this month's edition of eNews here


Appleyard Lees IP LLP has recently announced it has been recognised by three top legal industry analysts in the past month.


Eminent legal publishers Chambers & Partners 2021 has named Appleyard Lees a leading intellectual property firm for another consecutive year. Also, several Appleyard Lees attorneys are listed in IP Stars 2021, while The Legal 500 2021 has named Appleyard Lees a leading law firm for its patent and trade mark prosecution work.


In all three programmes, client feedback plays a large part in the research undertaken to rate a firm or attorney.

Neuroscience-focused CRO Transpharmation opening new facility at Discovery Park


Phase of expansion for company as it joins growing life sciences community on site


Sandwich, Kent, November 4 2020 - Discovery Park, the Life Sciences Opportunity Zone for ambitious and growing life sciences companies, is pleased to welcome contract research organisation Transpharmation Ltd as a new tenant. Its new facility will be Transpharmation’s largest laboratory. The company, which is focused on neuroscience research, has over 100 clients worldwide.


  • Aditum Bio, established by industry veterans Joe Jimenez and Mark Fishman, to fund clinical development

  • Sosei Heptares to receive an upfront payment and strategic equity stake in Tempero Bio, plus future success-based milestone payments and tiered royalties 

Cambridge, UK (November 2, 2020) — BioStrata, a specialist life science marketing and PR agency, has appointed a new senior team member to support continued and significant client growth in the United States. Jessica Grant, a B2B communications specialist with over 16 years’ experience, joins BioStrata as an Account Director based in Portland, Oregon, further building the company’s established global footprint.

Leaders in stem cell research and cell therapy to help drive development of scalable off-the-shelf therapies for diseases with a high unmet clinical need

RaDaR ctDNA liquid biopsy test to be used to monitor patient response in Phase 1/2 study of MVC-101 in multiple tumor types       


Research Triangle Park, NC, USA and Cambridge, UK, 29 October 2020 – Inivata, a leader in liquid biopsy, today announces a collaboration with Maverick Therapeutics (“Maverick”) for the use of Inivata’s RaDaR™ assay for the detection and monitoring of residual disease and recurrence. RaDaR will be used to monitor circulating tumor DNA (ctDNA) in patients enrolled in the Phase 1/2 study of MVC-101, Maverick’s lead program candidate.

• Announcing the challenge


This week the 7th CSP Blind Test begins - a major challenge in computational chemistry. It will see the world leading methods in Crystal Structure Prediction put to the test on real targets - with a high bar set by previous work. The 7 test systems have been sourced from leading experimentalists in industry and academia for prediction.


• The importance of CSP


The 3D structure and packing of crystalline materials have a big impact on their properties - this is most relevant in drug discovery and development.

Pages